CLINICAL TRIALS PROFILE FOR VINORELBINE TARTRATE

All Clinical Trials for VINORELBINE TARTRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002813 ↗	Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating patients with refractory or recurrent squamous cell cervical cancer that has not responded to local therapy.
NCT00002813 ↗	Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer	Completed	Gynecologic Oncology Group	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating patients with refractory or recurrent squamous cell cervical cancer that has not responded to local therapy.
NCT00003159 ↗	Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if surgery is more effective with or without preoperative chemotherapy in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying surgery and preoperative chemotherapy to see how well they work compared to surgery alone in treating patients with resectable non-small cell lung cancer.
NCT00002949 ↗	Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis	Completed	National Cancer Institute (NCI)	Phase 1	1996-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
NCT00002949 ↗	Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis	Completed	University of Chicago	Phase 1	1996-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
NCT00002887 ↗	Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer	Unknown status	Ottawa Regional Cancer Centre	Phase 1	1995-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells. PURPOSE: Phase I trial to study the effects of hydroxyurea plus combination chemotherapy in patients with non-small cell lung cancer.
NCT00002823 ↗	Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer	Completed	Gustave Roussy, Cancer Campus, Grand Paris	Phase 3	1995-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy following surgery with that of surgery alone in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer.

Clinical Trial Conditions for VINORELBINE TARTRATE

Condition Name

Condition Name for VINORELBINE TARTRATE
Intervention	Trials
Lung Cancer	22
Breast Cancer	11
Prostate Cancer	5
Lymphoma	5

Condition MeSH

Condition MeSH for VINORELBINE TARTRATE
Intervention	Trials
Lung Neoplasms	28
Carcinoma, Non-Small-Cell Lung	27
Breast Neoplasms	21
Hodgkin Disease	10

Clinical Trial Locations for VINORELBINE TARTRATE

Trials by Country

+

−

Trials by Country for VINORELBINE TARTRATE
Location	Trials
United States	570
Canada	51
United Kingdom	18
Australia	18
Italy	11

Trials by US State

+

−

Trials by US State for VINORELBINE TARTRATE
Location	Trials
California	24
Illinois	22
New York	22
Florida	18
Texas	18

Clinical Trial Progress for VINORELBINE TARTRATE

Clinical Trial Phase

Clinical Trial Phase for VINORELBINE TARTRATE
Clinical Trial Phase	Trials
Phase 3	22
Phase 2/Phase 3	2
Phase 2	41

Clinical Trial Status

Clinical Trial Status for VINORELBINE TARTRATE
Clinical Trial Phase	Trials
Completed	46
Unknown status	15
Terminated	11

Clinical Trial Sponsors for VINORELBINE TARTRATE

Sponsor Name

Sponsor Name for VINORELBINE TARTRATE
Sponsor	Trials
National Cancer Institute (NCI)	34
Children's Oncology Group	6
Alliance for Clinical Trials in Oncology	5

Sponsor Type

Sponsor Type for VINORELBINE TARTRATE
Sponsor	Trials
Other	84
NIH	35
Industry	21

Vinorelbine Tartrate: Clinical Trials, Market Analysis, and Projections

Introduction to Vinorelbine Tartrate

Vinorelbine tartrate is a potent anti-mitotic chemotherapy medication used to treat a variety of cancers, including breast cancer, non-small cell lung cancer (NSCLC), and other malignancies. Here, we will delve into the current clinical trials, market analysis, and future projections for this crucial drug.

Clinical Trials Update

Ongoing and Recent Trials

One significant clinical trial involving vinorelbine tartrate is the phase III trial for patients with high-risk rhabdomyosarcoma (RMS). This trial compares the safety and efficacy of adding vinorelbine to the standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy regimen. The study also examines the impact of maintenance therapy with or without vinorelbine on recurrence rates[1].

• Trial Design: Patients are randomized into two arms, with one arm receiving the standard VAC regimen and the other arm receiving VAC plus vinorelbine. Both arms include radiation therapy and maintenance therapy with vinorelbine and cyclophosphamide.
• Objectives: The primary goals are to assess the safety, efficacy, and impact on recurrence rates of adding vinorelbine to the standard treatment.

Other Clinical Trials

The European Union Clinical Trials Register and other databases list numerous clinical trials involving vinorelbine tartrate, focusing on its use in various cancer types, including NSCLC, breast cancer, and other malignancies. These trials often explore different dosages, combinations with other chemotherapy agents, and novel delivery systems to enhance efficacy and reduce side effects[4].

Market Analysis

Current Market Size and Growth

The global market for vinorelbine tartrate is experiencing significant growth driven by several factors:

• Increasing Incidence of Cancer: The rising prevalence of cancers such as NSCLC and breast cancer is a major driver. By 2024, the market is projected to reach USD 25.32 billion, with a compound annual growth rate (CAGR) of 9.33% expected between 2024 and 2031, leading to a valuation of USD 47.27 billion by 2031[2].
• Advances in Oncology: Improvements in cancer research and treatment options, including better formulations and delivery systems, are boosting demand for vinorelbine tartrate[2][3].

Market Segmentation

The vinorelbine market is segmented based on application, product type, and geographical regions:

• Application: Cancer treatment, chemotherapy, oncology, drug combination therapy, and cancer research.
• Product Type: Vinorelbine tartrate, vinorelbine injection, vinorelbine capsules, vinorelbine powder, and vinorelbine solution.
• Geographical Regions: North America, Europe, Asia-Pacific, South America, and the Middle East & Africa[3].

Key Players and Competitive Landscape

The market is dominated by several key players, including Hospira, Pfizer, Teva Pharmaceuticals, Mylan, Sandoz, Novartis, Accord Healthcare, Lupin Pharmaceuticals, Amgen, and Aurobindo Pharma. These companies are involved in various stages of vinorelbine production, from API manufacturing to final product distribution[3].

Market Projections

Future Growth and Trends

The vinorelbine tartrate market is expected to continue its upward trajectory due to several factors:

• Increasing Demand for Effective Treatments: The need for powerful chemotherapy medications like vinorelbine tartrate is driven by the rising incidence of cancer and advancements in oncology[2][3].
• Improved Formulations and Delivery Systems: Research into better drug delivery systems, such as liposomes, is expected to enhance the market by minimizing adverse effects and improving patient outcomes[2].
• Generic Manufacturers: The entry of generic manufacturers after patent expirations is anticipated to make vinorelbine tartrate more accessible and affordable, particularly in regions with limited healthcare resources[2].

API Market Projections

The global vinorelbine tartrate API market is projected to grow from USD 349 million in 2024 to USD 476.9 million by 2030, at a CAGR of 5.3% during the forecast period. Key manufacturers in this segment include Pierre Fabre, Hubei Hongyuan Pharmaceutical Technology, Hansoh Pharmaceutical Group, Minakem, Qilu Pharmaceutical, and others[5].

Key Takeaways

• Clinical Trials: Ongoing trials, such as the phase III trial for high-risk rhabdomyosarcoma, are evaluating the safety and efficacy of vinorelbine tartrate in combination with other chemotherapy agents.
• Market Growth: The global market for vinorelbine tartrate is expected to reach USD 47.27 billion by 2031, driven by the increasing incidence of cancer and advancements in oncology.
• Market Segmentation: The market is segmented by application, product type, and geographical regions, with key players dominating the landscape.
• Future Trends: Improved formulations, increased accessibility due to generic manufacturers, and ongoing research into new applications and delivery systems will continue to drive market growth.

FAQs

What is the primary use of vinorelbine tartrate in cancer treatment?

Vinorelbine tartrate is primarily used to treat various types of cancer, including non-small cell lung cancer (NSCLC), breast cancer, and rhabdomyosarcoma. It works by stopping cancer cells from growing and dividing.

What is the projected market size for vinorelbine tartrate by 2031?

The global market for vinorelbine tartrate is projected to reach USD 47.27 billion by 2031, growing at a CAGR of 9.33% from 2024 to 2031[2].

Which companies are key players in the vinorelbine tartrate market?

Key players include Hospira, Pfizer, Teva Pharmaceuticals, Mylan, Sandoz, Novartis, Accord Healthcare, Lupin Pharmaceuticals, Amgen, and Aurobindo Pharma[3].

How is the vinorelbine tartrate API market expected to grow?

The global vinorelbine tartrate API market is expected to grow from USD 349 million in 2024 to USD 476.9 million by 2030, at a CAGR of 5.3% during the forecast period[5].

What are the main factors driving the growth of the vinorelbine tartrate market?

The main factors include the increasing incidence of cancer, advancements in oncology, improved formulations, and the entry of generic manufacturers which will make the drug more accessible and affordable[2][3].

Are there any ongoing clinical trials for vinorelbine tartrate?

Yes, there are ongoing clinical trials, such as the phase III trial for high-risk rhabdomyosarcoma, which is comparing the safety and efficacy of adding vinorelbine to the standard VAC chemotherapy regimen[1].

Sources

1. A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma. Research-Studies.allinforhealth.info.
2. Buy Vinorelbine Tartrate: The market will reach USD 47.27 Billion. MedicaPharma.
3. Vinorelbine Market Size and Projections - Market Research Intellect. Market Research Intellect.
4. Search for vinorelbine tartrate - EU Clinical Trials Register. EU Clinical Trials Register.
5. Global Vinorelbine Tartrate API Market Insights, Forecast to 2030. Valuates Reports.